John Robert Perfect: Influence Statistics

John Robert Perfect

John Robert Perfect

Division of Infectious Diseases and Department of Medicine, Duke University Medical Center, Durham, NC, USA. | Division of Infectious Diseases and International Health, Duke ...

John Robert Perfect: Expert Impact

Concepts for which John Robert Perfect has direct influence: Cryptococcus neoformans , Invasive fungal infections , Cryptococcal meningitis , Fungal infections , Antifungal agents , Invasive candidiasis , United states .

John Robert Perfect: KOL impact

Concepts related to the work of other authors for which for which John Robert Perfect has influence: Cryptococcus neoformans , Fungal infections , Cryptococcal meningitis , Invasive aspergillosis , Aspergillus fumigatus , Candida albicans , Nitric oxide .

KOL Resume for John Robert Perfect

Year
2022

Division of Infectious Diseases and Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, United States

2021

Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

Duke University, Durham, NC

2020

Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, North Carolina, USA.

Duke University Medical Center, Durham, NC, USA

2019

Division of Infectious Disease, Department of Medicine, Duke University School of Medicine, Durham, NC, USA, View further author information

Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA

Duke University Medical Center, Durham, North Carolina

2018

Department of Medicine/Division of Infectious Diseases, Duke University, Durham, NC, USA

2017

Duke University Medical Center, Durham, North Carolina, United States of America

2016

Department of Medicine/Division of Infectious Diseases, Duke University, Durham, North Carolina.

Infectious Diseases, Duke University Medical Center, Durham, NC

2015

Division of Infectious Diseases, Duke University Medical Center, Durham, NC USA.

2014

Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, United States

Department of Medicine, Duke University Medical Centre, Durham, North Carolina, USA

Prominent publications by John Robert Perfect

KOL-Index: 19039 . OBJECTIVES: Clinical trial data indicate that posaconazole is superior to fluconazole (FLU) or itraconazole (ITRA) in preventing invasive fungal infections (IFIs) among neutropenic patients. Our objective was to assess the cost-effectiveness of posaconazole versus FLU or ITRA for prevention of IFIs among neutropenic patients. METHODS: We used modeling techniques to assess the ...
Known for Neutropenic Patients | United States | Invasive Fungal Infections | Flu Itra
KOL-Index: 18769 . An 8-person subcommittee of the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group evaluated available data on the treatment of cryptococcal disease. Opinion regarding optimal treatment was based on personal experience and information in the literature. The relative strength of each recommendation was graded according to the type and degree of evidence ...
Known for Cryptococcal Disease | Amphotericin Patients | Treatment Fluconazole | 10 Weeks
KOL-Index: 18706 . BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients ...
Known for Caspofungin Amphotericin | Invasive Candidiasis | Patients Neutropenia | Favorable Response
KOL-Index: 17778 . BACKGROUND: Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections. METHODS: In this randomized, multicenter study involving evaluators who were unaware of treatment assignments, we compared the efficacy and safety of posaconazole with those of ...
Known for Itraconazole Prophylaxis | Posaconazole Fluconazole | Patients Neutropenia | Myelodysplastic Syndrome
KOL-Index: 15897 . Cryptococcus neoformans is an opportunistic fungal pathogen that causes life-threatening infections of the central nervous system. Existing therapies include amphotericin B, fluconazole, and flucytosine, which are limited by toxic side effects and the emergence of drug resistance. We recently demonstrated that the protein phosphatase calcineurin is required for growth at 37 degrees C and ...
Known for Cryptococcus Neoformans | Calcineurin Fk506 | Antifungal Agents | Caspofungin Acetate
KOL-Index: 14971 . BACKGROUND: Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative. METHODS: In a randomized, international, multicenter trial, we compared voriconazole, a new second-generation triazole, with liposomal ...
Known for Liposomal Amphotericin | Persistent Fever | Patients Voriconazole | Empirical Antifungal
KOL-Index: 14672 . To assess the relationship between melanin production by Cryptococcus neoformans and virulence on a molecular basis, we asked: (a) is CNLAC1, the laccase structural gene of C. neoformans, expressed in vivo?; (b) can mouse virulence be restored to cnlac1 (Mel-) mutants by complementation with CNLAC1?; and (c) will targeted gene deletion of CNLAC1 decrease virulence for mice? Melanin is ...
Known for Cryptococcus Neoformans | Laccase Gene | Cnlac1 Virulence | Fungal Rna
KOL-Index: 14443 . The molecular chaperone Hsp90 orchestrates regulatory circuitry governing fungal morphogenesis, biofilm development, drug resistance, and virulence. Hsp90 functions in concert with co-chaperones to regulate stability and activation of client proteins, many of which are signal transducers. Here, we characterize the first Hsp90 co-chaperone in the leading human fungal pathogen, Candida ...
Known for Albicans Morphogenesis | Tolerance Resistance | Fungal Hsp90 | Client Proteins
KOL-Index: 14356 . Candida albicans is the leading fungal pathogen of humans, causing life-threatening disease in immunocompromised individuals. Treatment of candidiasis is hampered by the limited number of antifungal drugs whose efficacy is compromised by host toxicity, fungistatic activity, and the emergence of drug resistance. We previously established that the molecular chaperone Hsp90, which regulates ...
Known for Echinocandin Resistance | Hsp90 Function | Candida Albicans | Fungal Proteins
KOL-Index: 13761 . Fungal pathogens exploit diverse mechanisms to survive exposure to antifungal drugs. This poses concern given the limited number of clinically useful antifungals and the growing population of immunocompromised individuals vulnerable to life-threatening fungal infection. To identify molecules that abrogate resistance to the most widely deployed class of antifungals, the azoles, we conducted ...
Known for Fungal Pathogen Candida | Protein Kinase | Albicans Drug | Hsp90 Calcineurin
KOL-Index: 13606 . OBJECTIVE: To describe the safety and efficacy of voriconazole in children treated within the compassionate release program. METHODS: Children received voriconazole on a compassionate basis for treatment of an invasive fungal infection if they were refractory to or intolerant of conventional antifungal therapy. Voriconazole was administered as a loading dose of 6 mg/kg every 12 h i.v. on ...
Known for Invasive Fungal Infections | Voriconazole Treatment | Hematologic Malignancies | Chronic Granulomatous Disease
KOL-Index: 13549 . Cryptococcal meningitis is a fungal infection, caused by Cryptococcus neoformans, which is prevalent in immunocompromised patient populations. Treatment failures of this disease are emerging in the clinic, usually associated with long-term treatment with existing antifungal agents. The fungal cell wall is an attractive target for drug therapy because the syntheses of cell wall glucan and ...
Known for Cryptococcus Neoformans | Glucan Synthase | Essential Genes | Proteins Schizosaccharomyces
KOL-Index: 13506 . BACKGROUND: Lung transplantation has become an acceptable treatment option for many end-stage lung diseases. Pulmonary mycetomas are found in patients with end-stage lung diseases, especially sarcoidosis. The clinical course and long-term outcome of these patients after transplantation remains unknown. METHODS: We reviewed retrospectively the pathology reports of the explanted lungs from ...
Known for Lung Transplantation | Sarcoidosis Patients | Fungal Infections | Pulmonary Mycetomas
KOL-Index: 13424 . BACKGROUND: Hsp90 is an environmentally contingent molecular chaperone that influences the form and function of diverse regulators of cellular signaling. Hsp90 potentiates the evolution of fungal drug resistance by enabling crucial cellular stress responses. Here we demonstrate that in the leading fungal pathogen of humans, Candida albicans, Hsp90 governs cellular circuitry required not ...
Known for Albicans Morphogenesis | Pka Signaling | Filamentous Growth | Environmental Cues
KOL-Index: 13424 . The immunosuppressant FK506 (tacrolimus) is an antifungal natural product macrolide that suppresses the immune system by blocking T-cell activation. In complex with the intracellular protein FKBP12, FK506 inhibits calcineurin, a Ca(2+)-calmodulin-dependent serine-threonine protein phosphatase. We recently reported that growth of the opportunistic fungal pathogen Cryptococcus neoformans is ...
Known for Cryptococcus Neoformans | 37 Degrees | Immunosuppressant Fk506 | Nonimmunosuppressive Analog

Key People For Cryptococcus Neoformans

Top KOLs in the world
#1
John Robert Perfect
cryptococcus neoformans invasive fungal infections cryptococcal meningitis
#2
Arturo Casadevall
cryptococcus neoformans convalescent plasma extracellular vesicles
#3
Kyung Joo Kwon‐Chung
cryptococcus neoformans aspergillus fumigatus mating type
#4
Joseph Heitman
cryptococcus neoformans mating type sexual reproduction
#5
Françoise Dromer
cryptococcus neoformans titan cells antifungal agents
#6
Gary Matthew Cox
cryptococcus neoformans fungal genes mating type

Division of Infectious Diseases and Department of Medicine, Duke University Medical Center, Durham, NC, USA. | Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, North Carolina, USA | Division of Inf